Evidence of real-world effectiveness of erenumab against chronic migraine

Key clinical point: Erenumab is effective in managing patients with treatment-resistant chronic migraine in a tertiary care setting without causing any serious adverse effects.

Major finding: At 3 and 6 months, erenumab significantly reduced the median monthly migraine days (MMD; −4 and −9 days, respectively; P < .001), with the MMD 50% responder rate at 3 months being 36%. No serious adverse events were observed.

Study details: This was a prospective study including 92 patients aged >18 years with chronic migraine and ≥3 prior migraine preventive treatment failures who received monthly 70 mg erenumab for 3 months.

,

Disclosures: The authors did not report any source of funding or conflict of interests.

Source: Khalil M et al. Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real-world evidence. Eur J Neurol. 2022 (Apr 21). Doi: 10.1111/ene.15364